Open AccessCombating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy
Author(s) -
Casey D. Stefanski,
Jenifer R. Prosperi
Publication year - 2022
Publication title -
cancer drug resistance
Language(s) - English
Resource type - Journals
ISSN - 2578-532X
DOI - 10.20517/cdr.2021.128
Subject(s) - triple negative breast cancer , targeted therapy , breast cancer , cancer research , medicine , epidermal growth factor receptor , cancer , oncology , estrogen receptor , combination therapy , egfr inhibitors
Triple negative breast cancer (TNBC) is marked by a lack of expression of the Estrogen Receptor, Progesterone Receptor, and human epidermal growth factor receptor 2. Therefore, targeted therapies are being investigated based on the expression profiles of tumors. Due to the potential for acquired and intrinsic resistance, there is a need for combination therapy to overcome resistance. In the article by Lee et al., the authors identify that, while prexasertib (a CHK1 inhibitor) lacks efficacy alone, combination with an EGFR inhibitor provides synergistic anti-tumor effects. Advances in targeted therapy for TNBC will benefit the clinical landscape for this disease, with this study initiating a new avenue of investigation.